Prognostic value of baseline nailfold videocapillaroscopy in predicting pulmonary decline and disease progression in Systemic Sclerosis
- PMID: 40600932
- DOI: 10.1093/rheumatology/keaf361
Prognostic value of baseline nailfold videocapillaroscopy in predicting pulmonary decline and disease progression in Systemic Sclerosis
Abstract
Objectives: Systemic sclerosis (SSc) is a complex connective tissue disease frequently complicated by interstitial lung disease (ILD), which remains the leading cause of mortality. Nailfold videocapillaroscopy (NVC) is a widely used non-invasive technique for assessing microvascular damage in SSc, but its role in predicting ILD progression remains underexplored. Additionally, Krebs von den Lungen-6 (KL-6) has emerged as a potential biomarker for ILD severity, yet its relationship with NVC patterns and pulmonary function decline requires further investigation. To determine whether baseline NVC abnormalities predict pulmonary function decline, ILD progression, and longitudinal changes in serum biomarkers (KL-6, IL-18, IL-18BP), inflammatory markers, and disease activity indices (EUSTAR 2017, SCTC-DI) over a two-year follow-up in patients with SSc.
Methods: In this prospective longitudinal study, patients diagnosed with SSc according to the 2013 ACR/EULAR criteria were stratified based on the presence of ILD. Baseline assessments included NVC, high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), and serum biomarker measurements using quantitative ELISA. ILD progression was assessed by changes in forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), and HRCT findings. Correlations between baseline NVC abnormalities and longitudinal changes in pulmonary function, biomarkers, and disease indices were analyzed using multivariate regression modeling.
Results: 74 patients (27% male, mean age 57.5 ± 15 years) were included, with a mean disease duration of 7.67 ± 8 years. At baseline, 38% had ILD, which increased to 51% after two years, while the proportion with ≥20% lung involvement on HRCT rose from 32% to 43%. Disorganization of capillary architecture at baseline predicted greater declines in %FVC (β = -0.75, p = 0.03) and %DLCO (β = -0.24, p = 0.03), as well as worsening modified Rodnan skin score (mRSS) (β = 0.23, p = 0.03) over two years. A late NVC pattern was associated with worsened mRSS (β = 0.47, p = 0.004), larger increases in KL-6 (β = 0.18, p = 0.04), and more pronounced declines in %DLCO (β = -0.38, p = 0.04). Additionally, a higher baseline SCTC-DI score was predictive of progressive semiquantitative fibrosis on HRCT (β = -0.32, p = 0.003) and elevated CRP levels (β = 0.38, p = 0.003) at two years.
Conclusions: Baseline NVC abnormalities-particularly capillary disorganization and late pattern morphology-are independent predictors of ILD progression and worsening pulmonary function in SSc over two years in SSc. Elevated KL-6 levels further correlate with NVC abnormalities and pulmonary decline. These findings highlight the potential role of NVC as a non-invasive tool for ILD risk stratification, complementing traditional imaging and biomarker assessments. Early identification of patients at higher risk for ILD progression could enable more intensive monitoring and timely therapeutic interventions, improving long-term outcomes in SSc-ILD.
Keywords: NFC; systemic sclerosis: ILD.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study.Lancet Rheumatol. 2025 Jul;7(7):e463-e471. doi: 10.1016/S2665-9913(25)00026-8. Epub 2025 May 14. Lancet Rheumatol. 2025. PMID: 40381640
-
Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational study.Lancet Rheumatol. 2025 Mar;7(3):e178-e186. doi: 10.1016/S2665-9913(24)00236-4. Epub 2024 Nov 8. Lancet Rheumatol. 2025. PMID: 39527968
-
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251336896. doi: 10.1177/17534666251336896. Epub 2025 May 8. Ther Adv Respir Dis. 2025. PMID: 40337907 Free PMC article.
-
Stem cell transplantation for systemic sclerosis.Cochrane Database Syst Rev. 2022 Jul 29;7(7):CD011819. doi: 10.1002/14651858.CD011819.pub2. Cochrane Database Syst Rev. 2022. PMID: 35904231 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous